PL2001468T3 - Analogi tiazolidynodionu - Google Patents

Analogi tiazolidynodionu

Info

Publication number
PL2001468T3
PL2001468T3 PL07752982T PL07752982T PL2001468T3 PL 2001468 T3 PL2001468 T3 PL 2001468T3 PL 07752982 T PL07752982 T PL 07752982T PL 07752982 T PL07752982 T PL 07752982T PL 2001468 T3 PL2001468 T3 PL 2001468T3
Authority
PL
Poland
Prior art keywords
thiazolidinedione analogues
thiazolidinedione
analogues
Prior art date
Application number
PL07752982T
Other languages
English (en)
Inventor
Gerard R Colca
Rolf F Kletzien
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of PL2001468T3 publication Critical patent/PL2001468T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
PL07752982T 2006-03-16 2007-03-14 Analogi tiazolidynodionu PL2001468T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78289406P 2006-03-16 2006-03-16
EP07752982A EP2001468B1 (en) 2006-03-16 2007-03-14 Thiazolidinedione analogues
PCT/US2007/006321 WO2007109024A2 (en) 2006-03-16 2007-03-14 Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease

Publications (1)

Publication Number Publication Date
PL2001468T3 true PL2001468T3 (pl) 2013-03-29

Family

ID=38328199

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15151582T PL2902026T3 (pl) 2006-03-16 2007-03-14 Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie
PL07752982T PL2001468T3 (pl) 2006-03-16 2007-03-14 Analogi tiazolidynodionu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15151582T PL2902026T3 (pl) 2006-03-16 2007-03-14 Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie

Country Status (15)

Country Link
US (4) US20090143442A1 (pl)
EP (3) EP2486926A1 (pl)
JP (2) JP5269758B2 (pl)
KR (1) KR101475955B1 (pl)
CN (1) CN101454005B (pl)
AU (1) AU2007227581B2 (pl)
CA (1) CA2646207C (pl)
ES (2) ES2397944T3 (pl)
HU (1) HUE035314T2 (pl)
MX (2) MX2008011871A (pl)
NZ (1) NZ571871A (pl)
PL (2) PL2902026T3 (pl)
RU (1) RU2445957C2 (pl)
UA (1) UA96441C2 (pl)
WO (1) WO2007109024A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2902026T3 (pl) 2006-03-16 2018-03-30 Metabolic Solutions Development Company Llc Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie
EP2001469B1 (en) 2006-03-16 2012-05-23 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
NZ571872A (en) * 2006-03-16 2011-05-27 Metabolic Solutions Dev Co Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
ES2398313T3 (es) 2007-09-14 2013-03-15 Metabolic Solutions Development Company Llc 5-(4-(2-(3-metoxifenil)-2-oxoetoxi)bencil)tiazolidin-2,4-diona para uso en el tratamiento de la diabetes
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
SI2324126T1 (sl) 2008-08-12 2014-07-31 Zinfandel Pharmaceuticals, Inc. Postopek identifikacije dejavnikov tveganja za Alzheimerjevo bolezen
PL2512470T3 (pl) * 2009-12-15 2017-06-30 Octeta Therapeutics, Llc Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych
AU2010340058A1 (en) * 2009-12-15 2012-06-21 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
CA2783468C (en) 2009-12-15 2018-10-09 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB2477743A (en) * 2010-02-10 2011-08-17 Argenta Therapeutics Ltd Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds
CN102947269B (zh) 2010-04-19 2015-11-25 新陈代谢解决方案开发公司 噻唑烷二酮化合物的新的合成方法
RU2012148909A (ru) * 2010-04-19 2014-05-27 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Новый синтез соединений тиазолидиндиона
ES2609837T3 (es) 2010-08-10 2017-04-24 Octeta Therapeutics, Llc Nueva síntesis de compuestos de tiazolidindiona
MX342289B (es) * 2010-08-10 2016-09-23 Metabolic Solutions Dev Company Llc * Sintesis para compuestos de tiazolidindiona.
KR20180050420A (ko) 2011-01-10 2018-05-14 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
CA2894653A1 (en) * 2012-12-11 2014-06-19 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
CA2941562C (en) * 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
CN105764884B (zh) 2013-07-22 2019-01-18 新陈代谢解决方案开发公司 用于治疗代谢疾病的ppar-节制性化合物
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
HUE039555T2 (hu) 2014-04-02 2019-01-28 Minoryx Therapeutics S L 2,4-tiazolidindion származékok központi idegrendszer rendellenességeinek kezelésében
EA201991304A1 (ru) 2016-12-01 2019-12-30 Минорикс Терапьютикс С.Л. 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1985004170A1 (en) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1986002073A1 (en) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
CA2106967C (en) * 1991-04-11 2003-12-09 Takashi Sohda Thiazolidinedione derivatives, production and use thereof
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
CA2171827C (en) * 1993-09-15 2004-06-29 Jerrold Olefsky Use of thiazolidinediones to prevent or delay onset of niddm
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ286920A (en) 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
ATE355286T1 (de) 2001-04-26 2006-03-15 Zentiva As Verfahren zur herstellung von pioglitazone als antidiabetisches mitttel
US20070054902A1 (en) * 2003-12-02 2007-03-08 Shionogi & Co., Ltd. Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
NZ571872A (en) 2006-03-16 2011-05-27 Metabolic Solutions Dev Co Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
EP2001469B1 (en) 2006-03-16 2012-05-23 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
PL2902026T3 (pl) 2006-03-16 2018-03-30 Metabolic Solutions Development Company Llc Analogi tiazolidynodionu do leczenia choroby metabolicznej pośredniczonej przez zapalenie
ES2398313T3 (es) 2007-09-14 2013-03-15 Metabolic Solutions Development Company Llc 5-(4-(2-(3-metoxifenil)-2-oxoetoxi)bencil)tiazolidin-2,4-diona para uso en el tratamiento de la diabetes

Also Published As

Publication number Publication date
EP2001468A2 (en) 2008-12-17
ES2654908T8 (es) 2018-04-11
AU2007227581B2 (en) 2012-11-08
CN101454005A (zh) 2009-06-10
US9155729B2 (en) 2015-10-13
MX356584B (es) 2018-06-05
JP2013100371A (ja) 2013-05-23
PL2902026T3 (pl) 2018-03-30
CA2646207C (en) 2016-01-19
KR101475955B1 (ko) 2014-12-23
EP2001468B1 (en) 2012-10-31
EP2902026A1 (en) 2015-08-05
UA96441C2 (ru) 2011-11-10
RU2008140943A (ru) 2010-04-27
KR20090037381A (ko) 2009-04-15
CA2646207A1 (en) 2007-09-27
WO2007109024A2 (en) 2007-09-27
US20090143442A1 (en) 2009-06-04
CN101454005B (zh) 2013-01-02
EP2902026B1 (en) 2017-10-04
AU2007227581A1 (en) 2007-09-27
RU2445957C2 (ru) 2012-03-27
JP2009530283A (ja) 2009-08-27
NZ571871A (en) 2011-07-29
US8389556B2 (en) 2013-03-05
ES2397944T3 (es) 2013-03-12
MX2008011871A (es) 2009-02-10
EP2486926A1 (en) 2012-08-15
ES2654908T3 (es) 2018-02-15
JP5269758B2 (ja) 2013-08-21
US20120015982A1 (en) 2012-01-19
US20130203820A1 (en) 2013-08-08
HUE035314T2 (en) 2018-05-02
US20150190385A1 (en) 2015-07-09
WO2007109024A3 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
PL2001468T3 (pl) Analogi tiazolidynodionu
PL2001469T3 (pl) Analogi tiazolidynodionu
DE602007002700D1 (en) Interventionsfreies frac-system
IL180020A0 (en) Encryption -and decryption-enabled interfaces
DE602007002070D1 (en) 2-pyrazincarboxamidderivate
PL1849352T3 (pl) Kombajn
DE602007003855D1 (en) Isothermer reaktor
ZA200902278B (en) Aminomethyl-4-imidazoles
DE602007001601D1 (en) Glasuntersuchung
IL194495A0 (en) Thiazolyl-dihydroquinazolines
DE602007006989D1 (en) Spiropiperidinderivate
EP2062892A4 (en) AGENT ENHANCING HYPERTENSION
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
EP2030629A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
EP2060263A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
IL194493A0 (en) Thiazolyl dihydro-indazoles
GB2439623B (en) Tellmeuseby
ZA200708752B (en) Component
GB2474382B8 (en) Construction component
DE502007001126D1 (en) Eiten
AU4914P (en) CalflatGL Calothamnus quadrifidus
AU3514P (en) ARCBENT Arctotis fastuosa
GB0617866D0 (en) Jarjar (jaropener)
GB0611471D0 (en) Interface
EP2057992A4 (en) MEANS FOR IMPROVING THE KIDNEY FUNCTION